U.S. market Closed. Opens in 12 hours 4 minutes

REGN | Regeneron Pharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for REGN we got that it has strong fundamentals where Valuation is considered to be undervalued, Profitability is very wealthy, Growth is exceptionally good and Health is very strong.

Valuation (78%)

Company Industry
P/E Ratio (TTM) 16.55 -16.72
PEG Ratio (TTM) 2.28 -4.96
P/S Ratio (TTM) 5.56 47.85
P/B Ratio (TTM) 2.63 27.92
P/FCF Ratio (TTM) 22.79 -4.60
Price to 5YR AVG Earnings Ratio 17.29 -5.71
Price to 5YR AVG FCF Ratio 20.67 -12.95

Profitability (80%)

Company Industry
ROA (TTM) 12.43% -16.97%
ROE (TTM) 16.85% 27.85%
Net Profit Margin (TTM) 33.61% -848.99%
ROIC 5YR AVG 26.58% -22.40%

Growth (97%)

4QTR AVG 3YR AVG 5YR AVG
EPS 16.92% 64.50% 27.60%
Revenue 2.85% 38.13% 19.58%
Net Income 17.33% 60.82% 25.46%
Cash Flow 56.19% 62.97% 30.27%

Health (72%)

Company Industry
Current Ratio (TTM) 5.28 5.79
Quick Ratio (TTM) 4.46 5.57
D/E Ratio (TTM) 0.07 0.93
Interest Coverage (TTM) 63.56 -7.43
Piotroski F-Score 5 5
Altman Z-Score 8.16 12.96
LTL to 5YR AVG FCF 0.73 0.11
Shares Outstanding Growth 5YR AVG -1.43% 43.03%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙